Ethallobarbital

From WikiMD's WELLNESSPEDIA

Ethallobarbital.svg

Ethallobarbital is a barbiturate derivative that was developed in the early 20th century. It is known for its sedative and hypnotic properties, which make it useful in the treatment of insomnia and other sleep disorders.

Chemical Structure and Properties[edit]

Ethallobarbital belongs to the class of barbiturates, which are derivatives of barbituric acid. The chemical structure of ethallobarbital includes a pyrimidine ring fused with a urea moiety, and it is characterized by the presence of an ethyl group at the 5-position of the barbituric acid core.

Pharmacology[edit]

Ethallobarbital acts on the central nervous system (CNS) by enhancing the activity of the gamma-aminobutyric acid (GABA) neurotransmitter. This action results in increased GABA-ergic inhibition, leading to sedative and hypnotic effects. The drug is metabolized in the liver and excreted through the kidneys.

Medical Uses[edit]

Ethallobarbital has been used primarily for its sedative and hypnotic effects. It is prescribed for the short-term treatment of insomnia and for inducing anesthesia in medical procedures. Due to the risk of dependence and the development of safer alternatives, its use has declined over the years.

Side Effects and Risks[edit]

Common side effects of ethallobarbital include drowsiness, dizziness, and headache. Prolonged use can lead to tolerance, dependence, and withdrawal symptoms. Overdose can result in severe respiratory depression, coma, and even death.

History[edit]

Ethallobarbital was first synthesized in the early 20th century as part of the development of barbiturate drugs. It was one of many barbiturates used for their sedative and hypnotic properties before the advent of benzodiazepines and other modern sedatives.

Regulation[edit]

Due to its potential for abuse and dependence, ethallobarbital is classified as a controlled substance in many countries. Its use is strictly regulated, and it is available only by prescription.

See Also[edit]

References[edit]


Template:Barbiturates

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.